Broken String Biosciences Appoints Steve Becker as Chief Commercial Officer
24 Julio 2024 - 5:19AM
Business Wire
Appointment brings extensive experience to lead
commercial operations and accelerate growth in key global
markets
Broken String Biosciences (“Broken String”), a genomics company
driving development of the next generation of more precise, safe,
and effective cell and gene therapies, today announced it has
appointed Steve Becker as Chief Commercial Officer. An experienced
global life sciences executive, Steve will guide the expansion of
the Company’s commercial operations and implement a robust
go-to-market strategy for its Next-Generation Sequencing
(NGS)-based DNA break-mapping platform, INDUCE-seq®, as the Company
looks to strengthen its position across key markets.
Following the close of its $15M Series A funding round in 2023,
Broken String has been focused on delivering an ambitious expansion
strategy and revenue growth, including several high-profile
leadership appointments. Further bolstering the executive team,
Steve will direct the commercialization strategy for the INDUCE-seq
platform to ensure it meets the unique needs of the emerging cell
and gene therapy market, including development of a scalable
‘Platform as a Service’ offering and extension of the technology’s
capabilities beyond gene-editing. He will lead the global sales and
marketing teams, business development function, and technical
support operations, including building the Company’s US commercial
operations to nurture its growing network of customers and
commercial partners.
Steve is a renowned leader in the industry, with over 30 years’
experience managing diverse teams to develop scalable market
development strategies, across start-ups and multi-national
organizations. He has successfully launched numerous clinical
molecular diagnostics assays and spearheaded strategic growth
initiatives for premier life science tools companies. He joins
Broken String from Thermo Fisher Scientific, where he led the
licensing and commercial supply channel for the Genetic Sciences
and Clinical Oncology NGS divisions, responsible for building
commercial partnerships and managing large contract deals to expand
the Company’s global customer base. Prior to this, he held
executive level positions at Quest Diagnostics, Athena Diagnostics,
Inc. and RainDance Technologies, in addition to leadership roles at
Agilent Technologies and GE Healthcare.
Steve Becker, CCO, Broken String Biosciences, commented:
“What attracted me to Broken String Biosciences was its
game-changing technology and talented team of dedicated pioneers
changing the way we look at cell and gene therapy development. The
Company is at the forefront of the field, supporting developers to
ensure these transformative treatments can become a safe reality
for patients.” He added: “I’m keen to hit the ground running
as part of the leadership team, to build robust partnerships and
create an exceptional customer experience. I’m excited about the
role we will play in accelerating broad accessibility of cell and
gene therapies that will profoundly impact human health.”
Felix Dobbs PhD, CEO, Broken String Biosciences, said:
“We’re delighted that Steve is joining us to lead the Company’s
commercial activities based out of Boston MA. As we enter our next
stage of commercial growth and focus on establishing broad adoption
of the INDUCE-seq platform, Steve’s support will be pivotal in
executing the successful launch of our commercial offering, as well
as establishing strong partnerships with leading academic and
industry players in the genomics and cell & gene therapy
markets.”
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240724299052/en/
Jake Brown Zyme Communications E:
jake.brown@zymecommunications.com